GlassScriptPhysician profile
Warren Gabrillo
NPI 1982689295
$9,197.55
in general payments reported to CMS, 2019-2025
37 companies · $2,473 in 2025
The $2,473 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,134 · 2020: $623 · 2021: $537 · 2022: $853 · 2023: $702 · 2024: $1,877 · 2025: $2,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,951 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91.30 · Education: $8.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,951.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91.30 |
| Education | $8.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,475.29 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $797.21 | 2019-2025 | |
| Corcept Therapeutics | $575.77 | 2024-2025 | Korlym |
| Amgen INC. | $564.09 | 2020-2025 | Repatha, Krystexxa, Otezla |
| Abbott Laboratories | $534.05 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $516.66 | 2019 | |
| Glaxosmithkline, LLC. | $409.88 | 2022-2024 | Arexvy |
| Biohaven Pharmaceuticals, INC. | $278.83 | 2021 | |
| Esperion Therapeutics, INC. | $267.89 | 2021-2024 | Nexletol, Nexlizet |
| Phathom Pharmaceuticals, INC. | $261.47 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $258.31 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $246.82 | 2022-2024 | Rexulti |
| Medicure Pharma INC. | $239.01 | 2023-2024 | Zypitamag |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.27 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $220.89 | 2024 | Inpefa |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $204.77 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $201.65 | 2023-2025 | Ozempic |
| Xeris Pharmaceuticals, INC. | $198.56 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $194.61 | 2019-2020 | |
| Sanofi Pasteur INC. | $193.88 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $146.63 | 2022 | |
| Axsome Therapeutics, INC. | $140.61 | 2025 | Sunosi |
| Neurocrine Biosciences, INC. | $139.93 | 2025 | |
| Intra-Sana Laboratories | $124.99 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Sunovion Pharmaceuticals INC. | $122.09 | 2019 | |
| Smith+Nephew, INC. | $121.62 | 2019 | |
| Dexcom, INC. | $116.88 | 2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $88.15 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $63.40 | 2019 | |
| Edwards Lifesciences Corporation | $61.52 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lilly USA, LLC | $53.12 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $38.14 | 2019 | |
| Rgh Enterprises LLC | $34.00 | 2025 | |
| Inspire Medical Systems, INC. | $19.65 | 2024 | Inspire |
| Eisai INC. | $19.25 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.97 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $16.69 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Gabrillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.